The voltage-gated sodium channels (VGSCs) play a fundamental role in controlling cellular excitability and their abnormal activity is related to several pathological processes, including cardiac arrhythmias, epilepsy, neurodegenerative diseases, spasticity, chronic and neuropathic pain. In particular, neuropathic pain (e.g., postherpetic and trigeminal neuralgia, diabetic neuropathy and spinal cord injury) is a serious clinical problem that affects a high percentage of the world population. Because an altered sodium channel isoform expression profile has been considered one reason for the changes in neuronal excitability, there is a continuous quest for new selective molecules targeting sodium channels for the treatment of chronic pain. AREAS COVERED IN THIS REVIEW: PubMed, http://www.sciencedirect.com/ , SciFinder Scholar and http://ep.espacenet.com/ were used as sources for this review and patents between 2007 and September 2009 were taken into account for the sodium channel blockers molecular classes reviewed and discussed herein. WHAT THE READER WILL GAIN: The sodium channel blockers reported in this review have been categorized into different molecular classes on the basis of their wide structural diversity. This classification, somewhat arbitrary, does not necessarily reflect the presence of pharmacophoric elements but offers a useful way to discuss and comment on structurally homogenous classes of chemotypes recently patented. TAKE HOME MESSAGE: The continuous discoveries in the field of sodium channel blockers, highlighted by the increasing numbers of patent applications published in the last few years and by the numbers of compounds currently in clinical development, underline the importance of this target for the treatment of neuropathic pain. The great difficulty in the design of new selective and active structures, not obtained from old VGSC blockers that are often associated with high risk of adverse effects, is a strong challenge for medicinal chemistry research.

Sodium channel blockers for neuropathic pain / Zuliani, Valentina; Rivara, Mirko; M., Fantini; Costantino, Gabriele. - In: EXPERT OPINION ON THERAPEUTIC PATENTS. - ISSN 1354-3776. - 20:(2010), pp. 755-779. [10.1517/14728220802665734]

Sodium channel blockers for neuropathic pain.

ZULIANI, Valentina;RIVARA, Mirko;COSTANTINO, Gabriele
2010-01-01

Abstract

The voltage-gated sodium channels (VGSCs) play a fundamental role in controlling cellular excitability and their abnormal activity is related to several pathological processes, including cardiac arrhythmias, epilepsy, neurodegenerative diseases, spasticity, chronic and neuropathic pain. In particular, neuropathic pain (e.g., postherpetic and trigeminal neuralgia, diabetic neuropathy and spinal cord injury) is a serious clinical problem that affects a high percentage of the world population. Because an altered sodium channel isoform expression profile has been considered one reason for the changes in neuronal excitability, there is a continuous quest for new selective molecules targeting sodium channels for the treatment of chronic pain. AREAS COVERED IN THIS REVIEW: PubMed, http://www.sciencedirect.com/ , SciFinder Scholar and http://ep.espacenet.com/ were used as sources for this review and patents between 2007 and September 2009 were taken into account for the sodium channel blockers molecular classes reviewed and discussed herein. WHAT THE READER WILL GAIN: The sodium channel blockers reported in this review have been categorized into different molecular classes on the basis of their wide structural diversity. This classification, somewhat arbitrary, does not necessarily reflect the presence of pharmacophoric elements but offers a useful way to discuss and comment on structurally homogenous classes of chemotypes recently patented. TAKE HOME MESSAGE: The continuous discoveries in the field of sodium channel blockers, highlighted by the increasing numbers of patent applications published in the last few years and by the numbers of compounds currently in clinical development, underline the importance of this target for the treatment of neuropathic pain. The great difficulty in the design of new selective and active structures, not obtained from old VGSC blockers that are often associated with high risk of adverse effects, is a strong challenge for medicinal chemistry research.
2010
Sodium channel blockers for neuropathic pain / Zuliani, Valentina; Rivara, Mirko; M., Fantini; Costantino, Gabriele. - In: EXPERT OPINION ON THERAPEUTIC PATENTS. - ISSN 1354-3776. - 20:(2010), pp. 755-779. [10.1517/14728220802665734]
File in questo prodotto:
File Dimensione Formato  
abstract_exp_2010.pdf

non disponibili

Tipologia: Abstract
Licenza: Creative commons
Dimensione 10.97 kB
Formato Adobe PDF
10.97 kB Adobe PDF   Visualizza/Apri   Richiedi una copia
2010_exp_op_2010.pdf

non disponibili

Tipologia: Documento in Post-print
Licenza: Creative commons
Dimensione 1.48 MB
Formato Adobe PDF
1.48 MB Adobe PDF   Visualizza/Apri   Richiedi una copia

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11381/2312621
Citazioni
  • ???jsp.display-item.citation.pmc??? ND
  • Scopus 29
  • ???jsp.display-item.citation.isi??? 28
social impact